奥莱扎森用于管理严重高甘油三血症和胰腺炎风险
Nicholas A Marston1,2, Brian A Bergmark1,2, Veronica J Alexander3
1TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston.
The New England journal of medicine
|November 10, 2025
概括
在患有严重高甘油三血症的患者中,Olezarsen显著降低了甘油三水平和急性胰腺炎的发生率. 这种反意义的寡核酸对管理这种高风险人群有很大的希望.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 严重的高甘油三血症构成急性胰腺炎的重大风险.
- 针对阿波利波蛋白C-IIImRNA的反感性寡核酸olezarsen的治疗潜力仍在这个患者群体的研究中.
研究的目的:
- 为了评估olezarsen在患有严重高甘油三血症的患者中的疗效和安全性.
- 评估olezarsen对甘油三水平,脂质概况和急性胰腺炎发病率的影响.
主要方法:
- 进行了两项双盲,随机,安慰剂对照试验 (CORE-TIMI 72a和CORE2-TIMI 72b).
- 1061名患者每月接受olezarsen (50毫克或80毫克) 或安慰剂12个月.
- 主要结局:6个月后甘油三水平的百分比变化;次要结局:脂质变化和胰腺炎事件.
主要成果:
- 奥莱萨森在6个月 (高达-72.2%) 和12个月后显示了与安慰剂调整后,甘油水平的显著降低.
- 观察到阿波利波蛋白C-III,残留胆固醇和非HDL胆固醇水平在olezarsen下降.
- 有关急性胰腺炎的发病率与olezarsen显著降低 (发生率比率0.15;P<0.001).
结论:
- 治疗olezarsen导致显著降低甘油三和减少急性胰腺炎发病率在严重的高甘油三血症患者.
- 虽然一般耐受性很好,但80毫克的剂量显示肝酶升高和血小板减少.
- 服用olezarsen时,肝脏脂肪分数的剂量依赖性增加被观察到.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
Peptic Ulcer Disease IV: Management
419
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
419
Acute Pancreatitis II: Clinical Manifestations and Management
713
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
713
Chronic Pancreatitis II: Collaborative Care
303
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
303
Antiepileptic Drugs: Potassium Channel Activators
616
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
616


